Introduction
============

Upper urinary tract urothelial carcinoma (UUTUC) is a rare genitourinary malignancy that accounts for \~2% of all urinary tract tumors and 5% of urothelial carcinoma (UC).[@b1-ott-9-1399],[@b2-ott-9-1399] Radical nephroureterectomy (RNU) with bladder cuff excision represents the standard treatment for localized UUTUC.[@b3-ott-9-1399] However, the prognosis of patients who received RNU was poorer than that of those with bladder urothelial carcinoma. For patients with UUTUC with local muscular invasion, the 5-year disease-free survival (DFS) rate was 50%, and for those who had advanced disease, the rate decreased to 10%.[@b4-ott-9-1399]

Currently, recognized independent prognostic factors include tumor stage, tumor grade, extensive tumor necrosis, sessile tumor architecture, and lymphovascular invasion (LVI), which are mostly derived from postoperative data.[@b5-ott-9-1399]--[@b8-ott-9-1399] Some preoperative biomarkers, including serum creatinine and hemoglobin levels and Eastern Cooperative Oncology Group performance status, are recognized as independent prognostic factors in patients with UUTUC.[@b9-ott-9-1399] However, they are not sufficient to guide clinical decision making. Therefore, other reliable pretreatment prognostic factors are urgently needed. There is an increasing amount of evidence to support the role of systemic inflammation and inflammatory microenvironment in carcinogenesis and the development and progression of tumor.[@b10-ott-9-1399]--[@b13-ott-9-1399]

Some systemic inflammatory indicators have been introduced as prognostic markers in several types of cancer. Some cell types, such as neutrophils and lymphocytes, have been shown to predict the prognosis of various cancers.[@b14-ott-9-1399]--[@b16-ott-9-1399] Based on the numbers of circulating inflammatory cells, some indexes have been calculated and used as valuable prognostic predictors. For example, the neutrophil--lymphocyte ratio (NLR) has been suggested as a prognostic indicator for lung, colorectal, breast, and urinary cancers and hepatocellular carcinoma.[@b17-ott-9-1399]--[@b21-ott-9-1399] Platelet--lymphocyte ratio (PLR) is another valuable predictor, which has been validated in gastric cancer, intrahepatic cholangiocarcinoma, pancreatic ductal adenocarcinoma, and ovarian cancer.[@b22-ott-9-1399]--[@b26-ott-9-1399] In addition, the lymphocyte--monocyte ratio (LMR) has diagnostic value in cervical cancer, renal cell carcinoma, UUTUC, lung cancer, and esophageal squamous cell carcinoma.[@b27-ott-9-1399]--[@b30-ott-9-1399] Although NLR, PLR, and LMR can be used as outcome predictors, few studies have compared their prognostic value in UUTUC simultaneously.

In this study, we compared the prognostic value of preoperative NLR, PLR, and LMR in patients with UUTUC.

Materials and methods
=====================

Study subjects
--------------

We retrospectively reviewed the clinicopathological data of patients with UUTUC who underwent RNU with bladder cuff excision at the Affiliated Hospital of Qingdao University between January 2005 and December 2011. Patients who received adjuvant chemotherapy or radiotherapy, had clinical evidence of infection, or had advanced disease were excluded from the study. We assessed the data from a final total of 140 patients. Data regarding age, sex, smoking status, history of hypertension and diabetes, history of adjuvant chemotherapy and radiotherapy, tumor location, previous or concomitant bladder cancer, LVI, tumor necrosis, hematuria, hydronephrosis, tumor--node--metastasis staging, and differential grade were obtained from medical records. Staging was assessed according to the tumor--node--metastasis classification, and grading was assessed according to the World Health Organization guidelines.[@b31-ott-9-1399] We obtained cell counts from routine blood tests that were carried out within 3 days before surgery. Disease recurrence was defined as local treatment failure and lymph node and distant metastases. Bladder recurrence was excluded from the analysis of progression-free survival (PFS). The last follow-up date was March 30, 2015.

All patients gave written informed consent. The study was approved by the Institutional Review Board of the Affiliated Hospital of Qingdao University.

Statistical analysis
--------------------

NLR was obtained by dividing absolute neutrophil count by absolute lymphocyte count, LMR by dividing absolute lymphocyte count by absolute monocyte count, and PLR by dividing absolute platelet count by absolute lymphocyte count. The study endpoint was DFS. We plotted receiver operating characteristic (ROC) curves of NLR, PLR, and LMR for the diagnosis of tumor recurrence. The relationships between NLR, LMR, and PLR and other clinicopathological parameters were compared by Pearson's *χ*^2^ test. DFS and PFS curves were drawn by the Kaplan--Meier method and evaluated by the log-rank test. Univariate and multivariate analyses were performed using the log-rank test and Cox proportional hazards regression models. A value of *P*\<0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS Version 19.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

Among the 140 patients, there were 86 males and 54 females, with a median age of 67 years (range: 39--81 years), and the median survival time was 45 months (range: 11--108 months). Thirty patients were lost to follow-up \>10 years. Twenty-seven patients died from cancer-related causes, and six from a traffic accident, myocardial infarction, or natural causes. Thirty-five patients had tumor recurrence or metastasis.

For the 140 patients with UUTUC, an NLR of 2.2 calculated by ROC curve showed the best sensitivity and specificity ([Figure 1A](#f1-ott-9-1399){ref-type="fig"}). Based on the cutoff value of 2.2, 63 patients (45%) had an elevated preoperative NLR. The area under the curve (AUC) for NLR was 0.759 (95% confidence interval \[CI\]: 0.671--0.846, *P*\<0.001). A PLR of 128 showed the best sensitivity and specificity on the ROC plot ([Figure 1B](#f1-ott-9-1399){ref-type="fig"}). Forty-seven patients (33.6%) had an elevated preoperative PLR. The AUC for PLR was 0.659 (95% CI: 0.553--0.765, *P*=0.005). The cutoff value of LMR was 3.6, with an AUC of 0.717 (95% CI: 0.620--0.814, *P*\<0.001; [Figure 1C](#f1-ott-9-1399){ref-type="fig"}). Our data showed that NLR was superior to PLR and LMR as a predictive factor in patients with UUTUC undergoing RNU.

The cutoff values of LMR, NLR, and PLR derived from the ROC curves were used to divide the patients into high- and low-LMR, low-NLR and low-PLR groups. The relationships between clinicopathological parameters and NLR, LMR, or PLR are shown in [Table 1](#t1-ott-9-1399){ref-type="table"}. Preoperative NLR was significantly higher in pathological tumor (pT) 3/4 stage UUTUC (*P*\<0.001). For patients with pT 3/4 stage UUTUC or LVI, preoperative PLR was elevated significantly (*P*=0.002, *P*=0.028). Decreased preoperative LMR was significantly associated with old age (*P*=0.004) and advanced pT stage (*P*\<0.001).

The 5-year DFS rate in the high-NLR (≥2.2) group was significantly lower than in the low-NLR (\<2.2) group (54.3% vs 88.2%; [Figure 2A](#f2-ott-9-1399){ref-type="fig"}). The 5-year DFS rate in the high-PLR (≥128) group was significantly lower than in the low-PLR (\<128) group (63.9% vs 80.6%; [Figure 2B](#f2-ott-9-1399){ref-type="fig"}). The 5-year DFS rate in the low-LMR (\<3.6) group was significantly lower than in the high-LMR (≥3.6) group (53.4% vs 89.8%; [Figure 2C](#f2-ott-9-1399){ref-type="fig"}). Similarly, the 5-year PFS rate was 55.3% for the high-NLR (≥2.2) group and 89.9% for the low-NLR (\<2.2) group ([Figure 2D](#f2-ott-9-1399){ref-type="fig"}). The 5-year PFS rate was 65.1% for the high-PLR (≥128) group and 81.2% for the low PLR (\<128) group ([Figure 2E](#f2-ott-9-1399){ref-type="fig"}). The 5-year PFS rate was 59.1% for the low-LMR (\<3.6) group and 87.0% for the high-LMR (≥3.6) group ([Figure 2F](#f2-ott-9-1399){ref-type="fig"}).

As shown in [Table 2](#t2-ott-9-1399){ref-type="table"}, univariate analysis revealed that age (*P*=0.001 and *P*=0.009), smoking (*P*=0.007 and *P*=0.015), LVI (*P*=0.001 and *P*\<0.001), pathological stage (*P*\<0.001 and *P*\<0.001), NLR (*P*\<0.001 and *P*\<0.001), PLR (*P*=0.01 and *P*\<0.001), and LMR (*P*\<0.001 and *P*\<0.001) were significantly associated with DFS and PFS, respectively. Differential grade was significantly associated with PFS (*P*=0.018). Multivariate analysis indicated that pathological stage, NLR, and LMR were identified as independent prognostic factors for DFS (*P*\<0.001, *P*=0.035, and *P*=0.002) and PFS (*P*\<0.001, *P*=0.005, and *P*=0.002; [Table 3](#t3-ott-9-1399){ref-type="table"}). In addition, smoking was identified as an independent prognostic factor for DFS (*P*=0.024).

Discussion
==========

Since Coussen and Werb proposed that tumor formation is derived from chronic inflammation, many studies have shown that inflammation is related to the development and progression of cancer.[@b12-ott-9-1399],[@b13-ott-9-1399],[@b32-ott-9-1399]

As critical cellular components of human immunity, peripheral leukocytes, and platelets play an important role in carcinogenesis. Neutrophilia is associated with malignancy, because neutrophils produce circulating vascular endothelial cell growth factor; the overexpression of which promotes the formation of tumor blood vessels. Cytokines, including interleukin-1, interleukin-6, and tumor necrosis factor, may cause elevation of neutrophilia.[@b33-ott-9-1399],[@b34-ott-9-1399] Lymphocytes are the main components of antitumor immunity, and their reduction may cause abnormal immune function and reduce antitumor immunity. With the help of CD4^+^ T-cells, CD8^+^ T-cells can control tumor growth by cytotoxic activity and inducing apoptosis of tumor cells.[@b34-ott-9-1399] The low level of lymphocyte infiltration in cancer-adjacent tissues is conducive to the proliferation and metastasis of cancer cells, thus affecting the prognosis of tumor patients.[@b35-ott-9-1399] As major cellular components, platelets also have an important role in cancer progression and metastasis. Platelets can facilitate amplification of cancer-related coagulation by providing a procoagulant surface or working synergistically with elevated fibrinogen and can accumulate to protect tumor cells from immune responses.[@b36-ott-9-1399],[@b37-ott-9-1399] Some researchers believe that platelets function as dynamic reservoirs of proangiogenic and antiangiogenic proteins.[@b38-ott-9-1399] Monocytes can initiate tumorigenesis by producing high levels of reactive oxygen and nitrogen species, which can react with DNA and promote tumor progression and metastasis by releasing a large number of cytokines.[@b39-ott-9-1399]

Some novel inflammatory indicators can be established by combining peripheral blood cell counts, such as NLR, LMR, and PLR, which have been investigated for their predictive prognostic value in malignant tumors. The prognostic values of NLR, LMR, and PLR have also been studied in UUTUC. Dalpiaz et al[@b40-ott-9-1399] reported that high NLR (≥2.7) was significantly associated with shorter cancer-specific survival (CSS) and overall survival (OS) rates in univariate analysis, and NLR was an independent maker for CSS and OS. Azuma et al[@b41-ott-9-1399] revealed that recurrence-free survival and CSS rates of patients in the high-NLR group (≥2.5) were lower than those in the low-NLR group (\<2.5). They also showed that NLR is an independent risk factor for recurrence-free survival and CSS. Using a cutoff value of 3.0, NLR was also an independent risk factor for CSS.[@b42-ott-9-1399],[@b43-ott-9-1399] Consistent with the aforemntioned results, we validated preoperative NLR as a prognostic marker in UUTUC. Using a cutoff value of 2.2, the patients in the high-NLR group had poorer DFS and PFS than those in the low-NLR group. In the multivariate analysis, NLR was also an independent risk factor for DFS and PFS.

The prognostic value of LMR has been identified in many malignant tumors, such as renal cell carcinoma, esophageal squamous cell carcinoma, and lung cancer,[@b27-ott-9-1399],[@b30-ott-9-1399],[@b44-ott-9-1399] but only rarely in UUTUC. To the best of our knowledge, only one study has examined the prognostic value of LMR in patients with UUTUC.[@b28-ott-9-1399] LMR, age, and pathological T-stage were independent predictors of OS in patients with UUTUC.[@b28-ott-9-1399] Similarly, we found that LMR could be an independent predictor of DFS and PFS in patients with UUTUC.

PLR is another index of systemic inflammation that has been validated as a prognostic predictor in some tumors, including colorectal and ovarian cancer and pancreatic ductal adenocarcinoma.[@b45-ott-9-1399]--[@b47-ott-9-1399] However, to date, no study has specifically investigated the significance of PLR in UUTUC. Our study is believed to be the first to show that elevated PLR (≥128) was significantly associated with LVI, which is considered to be an independent factor for the prognosis in UUTUC.[@b5-ott-9-1399],[@b6-ott-9-1399] This indicates that PLR may be associated with prognosis of UUTUC. However, in multivariate analysis, we could not prove that PLR was an independent factor in UUTUC.

We compared NLR, PLR, and LMR to evaluate survival outcomes in patients with UUTUC simultaneously. All three makers had a significant association with pathological T stage; LMR was significantly associated with age, and PLR was significantly associated with LVI. European guidelines on UUTUC state that tumor stage and grade, age, LVI, extensive tumor necrosis, tumor architecture (eg, papillary vs sessile), concomitant carcinoma in situ, and some molecular markers such as microsatellite instability are closely related to the prognosis of UUTUC.[@b31-ott-9-1399] With good association with pathological T stage, LVI, or age, NLR, PLR, and LMR may have a good relationship with prognosis of UUTUC. In multivariate analysis, we concluded that both NLR and LMR were independent predictors of DFS and PFS. Kim et al[@b48-ott-9-1399] studied the prognostic value of systemic inflammatory responses in patients with UUTUC. They found that both NLR and PLR had no relationship with prognosis of UUTUC. However, they demonstrated that derived NLR (neutrophil count/white cell count--neutrophil count) was an independent prognostic factor, which was consistent with the findings of Proctor et al.[@b49-ott-9-1399] Our results differed from those of Kim et al. This was partly because of the difference in the study design and ethnic diversity. Kim et al selected 5.0 and 150 as cutoff values of NLR and PLR empirically, which differed from 2.2 to 128 that were calculated by the ROC curve in our study. The patients in our study were Chinese, whose tumor characteristics were different from those of foreign patients.

It is crucial to select suitable cutoff values of NLR, PLR, and LMR. Almost all studies determined their cutoff values empirically, which differed from each other significantly. Unlike previous studies, we used the ROC curve to determine the ideal cutoff values of NLR, PLR, and LMR. We concluded that NLR was superior to PLR and LMR as a predictive factor in patients with UUTUC undergoing RNU; the AUC of NLR was 0.759, which was superior to 0.659 of PLR and 0.717 of LMR.

There were some limitations to our study. First, this was a retrospective study, and because the patients were not treated by the same doctor it was difficult to ensure the consistency of the clinicopathological data. Second, even if we excluded the effects of inflammation and other factors on the inflammatory cell counts, we could not guarantee that all the interference factors were excluded. Third, OS was another important indicator of prognosis but was not taken into account. Fourth, in our survival analysis, we could not adjust for confounding variables such as the association between clinical factors (age, stage, or LVI) and LMR, NLR, or PLR. Therefore, the results of our survival analysis may be less accurate than that of the survival analysis that could adjust for the association. Additionally, some other clinicopathological parameters, such as tumor architecture (eg, papillary vs sessile), and concomitant carcinoma in situ, were not included in our study. In addition, all patients enrolled in our study were Chinese, so we cannot eliminate the influence of ethnic diversity. Finally, our study sample was small, and the significance of NLR, PLR, and LMR needs to be verified by a large sample.

Conclusion
==========

This is believed to be the first study to compare the prognostic value of NLR, LMR, and PLR in patients with UUTUC who underwent RNU. We confirmed that NLR and LMR could be independent predictors of DFS and PFS. According to the ROC curves, NLR was a superior predictive factor to LMR. These findings need prospective studies to be validated.
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![ROC curves for survival prediction.\
**Notes:** ROC curves were plotted to verify the accuracy of NLR, PLR, and LMR for survival. (**A**) ROC curves of NLR for survival prediction. (**B**) ROC curves of PLR for survival prediction. (**C**) ROC curves of LMR for survival prediction.\
**Abbreviations:** LMR, lymphocyte--monocyte ratio; NLR, neutrophil--lymphocyte ratio; PLR, platelet--lymphocyte ratio; ROC, receiver operating characteristic.](ott-9-1399Fig1){#f1-ott-9-1399}

![Kaplan--Meier curves for DFS and PFS of patients with UUTUC.\
**Notes:** (**A**) DFS curves of patients with UUTUC in the low-NLR group (\<2.2) vs the high-NLR group (≥2.2), *P*\<0.001; (**B**) DFS curves of patients with UUTUC in the low-PLR group (\<128) vs the high-PLR group (≥128), *P*=0.01; (**C**) DFS curves of patients with UUTUC in the high-LMR group (≥3.6) vs the low-LMR group (\<3.6), *P*\<0.001. (**D**) PFS curves of patients with UUTUC in the low-NLR group (\<2.2) vs the high-NLR group (≥2.2), *P*\<0.001; (**E**) PFS curves of patients with UUTUC in the low-PLR group (\<128) vs the high-PLR group (≥128), *P*\<0.001; (**F**) PFS curves of patients with UUTUC in the high-LMR group (≥3.6) vs the low-LMR group (,3.6), *P*\<0.001.\
**Abbreviations:** DFS, disease-free survival; LMR, lymphocyte--monocyte ratio; NLR, neutrophil--lymphocyte ratio; PFS, progression-free survival; PLR, platelet--lymphocyte ratio; UUTUC, upper urinary tract urothelial carcinoma.](ott-9-1399Fig2){#f2-ott-9-1399}

###### 

Relationships between clinicopathological parameters and NLR, LMR, or PLR

  Variable               NLR ≥2.2   NLR \<2.2   *P*-value                                         PLR ≥128   PLR \<128   *P*-value                                         LMR ≥3.6   LMR \<3.6   *P*-value
  ---------------------- ---------- ----------- ------------------------------------------------- ---------- ----------- ------------------------------------------------- ---------- ----------- -------------------------------------------------
  Age (years)                                   0.618                                                                    0.427                                                                    0.004
   \<70                  35         46                                                            25         56                                                            28         53          
   ≥70                   28         31                                                            22         37                                                            35         24          
  Sex                                           0.197                                                                    0.491                                                                    0.807
   Male                  35         51                                                            27         59                                                            38         48          
   Female                28         26                                                            20         34                                                            25         29          
  Smoking status                                0.707                                                                    0.571                                                                    0.133
   Yes                   17         23                                                            12         28                                                            22         18          
   No                    46         54                                                            35         65                                                            41         59          
  Hypertension                                  0.071                                                                    0.415                                                                    0.27
   Yes                   29         24                                                            20         33                                                            27         26          
   No                    34         53                                                            27         60                                                            36         51          
  Diabetes                                      0.225                                                                    0.599                                                                    0.794
   Yes                   12         9                                                             6          15                                                            10         11          
   No                    51         68                                                            41         78                                                            53         66          
  Tumor location                                0.551                                                                    0.134                                                                    0.268
   Left                  31         34                                                            26         39                                                            26         39          
   Right                 32         43                                                            21         54                                                            37         38          
  Tumor necrosis                                0.205[a](#tfn1-ott-9-1399){ref-type="table-fn"}                          1[a](#tfn1-ott-9-1399){ref-type="table-fn"}                              0.819
   Present               3          2                                                             2          3                                                             3          2           
   Absent                60         75                                                            45         90                                                            60         75          
  Hematuresis                                   0.389                                                                    0.974                                                                    0.254
   Present               46         61                                                            36         71                                                            51         56          
   Absent                17         16                                                            11         22                                                            12         21          
  Hydronephrosis                                0.285                                                                    0.593                                                                    0.756
   Present               40         42                                                            29         53                                                            36         46          
   Absent                23         35                                                            18         40                                                            27         31          
  Bladder cancer                                0.317                                                                    0.347[a](#tfn1-ott-9-1399){ref-type="table-fn"}                          0.115
   Yes                   7          5                                                             6          6                                                             8          4           
   No                    55         72                                                            41         87                                                            55         73          
  Tumor grade                                   0.284                                                                    0.372                                                                    0.696
   1/2                   27         40                                                            20         47                                                            29         38          
   3                     36         37                                                            27         46                                                            34         39          
  Pathological T stage                          0.000                                                                    0.002                                                                    0.000
   a-2                   28         60                                                            21         67                                                            27         61          
   3/4                   35         17                                                            26         26                                                            36         16          
  LVI                                           0.502[a](#tfn1-ott-9-1399){ref-type="table-fn"}                          0.028[a](#tfn1-ott-9-1399){ref-type="table-fn"}                          0.131[a](#tfn1-ott-9-1399){ref-type="table-fn"}
   Present               4          2                                                             5          1                                                             5          1           
   Absent                59         75                                                            42         92                                                            58         76          

**Note:**

Continuity correction *χ*^2^ test.

**Abbreviations:** LMR, lymphocyte--monocyte ratio; LVI, lymphovascular invasion; NLR, neutrophil--lymphocyte ratio; PLR, platelet--lymphocyte ratio.

###### 

Univariate analysis of DFS and PFS in 140 patients with upper urinary tract urothelial carcinoma

  Variable               n     DFS      PFS              
  ---------------------- ----- -------- ------- -------- -------
  Age (years)                                            
   \<70                  81    10.734   0.001   6.828    0.009
   ≥70                   59                              
  Sex                                                    
   Male                  86    0.09     0.765   0.226    0.635
   Female                54                              
  Smoking status                                         
   Yes                   40    7.297    0.007   5.924    0.015
   No                    100                             
  Hypertension                                           
   Yes                   53    0.011    0.917   0.277    0.599
   No                    87                              
  Diabetes                                               
   Yes                   21    0.011    0.915   0.655    0.418
   No                    119                             
  Tumor location                                         
   Left                  65    2.106    0.147   0.222    0.637
   Right                 75                              
  Tumor necrosis                                         
   Yes                   5     1.351    0.245   0.766    0.382
   No                    135                             
  Hematuresis                                            
   Yes                   107   0.05     0.822   0.054    0.816
   No                    33                              
  Hydronephrosis                                         
   Yes                   82    0.099    0.753   0.038    0.846
   No                    58                              
  Bladder cancer                                         
   Yes                   12    0.595    0.441   2.27     0.132
   No                    128                             
  Tumor grade                                            
   1/2                   67    2.689    0.101   5.64     0.018
   3                     73                              
  Pathological T stage                                   
   a-2                   88    44.272   0.000   60.893   0.000
   3/4                   52                              
  LVI                                                    
   Yes                   6     11.551   0.001   12.549   0.000
   No                    134                             
  NLR                                                    
    ≥2.2                 63    14.473   0.000   28.806   0.000
   \<2.2                 77                              
  PLR                                                    
    ≥128                 47    6.7      0.01    17.071   0.000
   \<128                 93                              
  LMR                                                    
    ≥3.6                 77    17.841   0.000   26.635   0.000
   \<3.6                 63                              

**Abbreviations:** DFS, disease-free survival; LMR, lymphocyte--monocyte ratio; NLR, neutrophil--lymphocyte ratio; PFS, progression-free survival; PLR, platelet--lymphocyte ratio; LVI, lymphovascular invasion.

###### 

Multivariate analysis of DFS and PFS in 140 patients with upper urinary tract urothelial carcinoma

  Variables              DFS     PFS                                      
  ---------------------- ------- ------- --------------- ------- -------- ---------------
  Sex                    0.061   0.312   0.092--1.055    0.356   0.616    0.220--1.723
  Age                    0.197   1.865   0.724--4.802    0.548   1.259    0.594--2.665
  Smoking                0.024   4.193   1.208--14.555   0.112   2.231    0.829--6.001
  Hypertension           0.598   0.771   0.293--2.026    0.602   0.798    0.342--1.863
  Diabetes               0.861   0.890   0.241--3.282    0.712   1.198    0.459--3.129
  Pathological T stage   0.000   9.279   2.776--31.017   0.000   10.110   3.582--28.529
  Tumor grade            0.924   1.049   0.389--2.828    0.535   1.313    0.556--3.101
  LVI                    0.150   4.898   0.563--42.626   0.228   3.165    0.487--20.565
  Bladder cancer         0.450   0.547   0.114--2.619    0.866   1.111    0.328--3.760
  Tumor necrosis         0.551   0.392   0.018--8.488    0.700   1.613    0.141--18.413
  Tumor location         0.727   0.838   0.311--2.261    0.406   1.461    0.598--3.570
  Hematuresis            0.182   2.384   0.665--8.540    0.084   2.514    0.885--7.139
  Hydronephrosis         0.659   1.258   0.455--3.476    0.562   1.304    0.532--3.195
  NLR                    0.035   0.326   0.115--0.924    0.005   3.819    1.494--9.761
  PLR                    0.431   1.441   0.580--3.582    0.053   2.234    0.990--5.042
  LMR                    0.002   6.307   1.938--20.530   0.002   4.909    1.804--13.358

**Abbreviations:** CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; LMR, lymphocyte--monocyte ratio; LVI, lymphovascular invasion; NLR, neutrophil--lymphocyte ratio; PFS, progression-free survival; PLR, platelet--lymphocyte ratio.
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